Condition: Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M) · Locally Advanced Laryngeal Squamous Cell Carcinoma · Hypopharyngeal Squamous Cell Carcinoma · Sponsor: Matthew Spector
This trial will study the safety and tolerability and disease survival rates in adult patients with recurrent/metastatic (R/M) HNSCC when treated with carboplatin or cisplatin, paclitaxel, and toripalimab.
This description comes directly from the study's public registry record.
Jennifer Ruth, RN, BSN, CCRP · 412-623-8963 · ruthj2@upmc.edu
Mel J Mendez, BS · 878-261-6071 · mendezmj@upmc.edu
Always discuss trial participation with your own doctor first.
| UPMC Hillman Cancer | Pittsburgh, Pennsylvania, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07423078